Vergelijking

Mazdutide vs. VK2735

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

2259884-03-0

geen gegevens

Molecuulmassa

4790 g/mol

geen gegevens

Halfwaardetijd

132 h

geen gegevens

Sequentie

synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkette

geen gegevens

Werkingsmechanisme

Mazdutide

Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Mazdutide	VK2735
CN	Op recept	—
Duitsland	Alleen onderzoek	Niet goedgekeurd
Verenigde Staten	Alleen onderzoek	Niet goedgekeurd

Volledige vermeldingen

Mazdutide

Volledige vermelding →

VK2735

Volledige vermelding →

Frequently asked questions

What is the difference between Mazdutide and VK2735?: Mazdutide is classified as "Metabool", while VK2735 is classified as "Metabool". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Mazdutide or VK2735?: The highest available evidence level is "Humane RCT" for Mazdutide and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Mazdutide and VK2735 in Germany and the United States?: Duitsland: Mazdutide — Alleen onderzoek, VK2735 — Niet goedgekeurd. Verenigde Staten: Mazdutide — Alleen onderzoek, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Mazdutide

VK2735

Op recept

—

Duitsland

Alleen onderzoek

Niet goedgekeurd

Verenigde Staten

Alleen onderzoek

Niet goedgekeurd

Frequently asked questions

What is the difference between Mazdutide and VK2735?

Mazdutide is classified as "Metabool", while VK2735 is classified as "Metabool". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Mazdutide or VK2735?

The highest available evidence level is "Humane RCT" for Mazdutide and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Mazdutide and VK2735 in Germany and the United States?

Duitsland: Mazdutide — Alleen onderzoek, VK2735 — Niet goedgekeurd. Verenigde Staten: Mazdutide — Alleen onderzoek, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.